A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs ARGX 113 (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Proof of concept
  • Sponsors argenx
  • Most Recent Events

    • 31 Mar 2017 According to a argenx media release, first patient has been dosed and top line data expected in second half of 2018.
    • 31 Mar 2017 Status changed from planning to recruiting, according to a argenx media release.
    • 09 Jan 2017 According to an arGEN-X media release, company plans to initiate this study by the end of first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top